Epigenomics AG
XHAM:ECX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Epigenomics AG
XHAM:ECX
|
DE |
|
S
|
Starteck Finance Ltd
BSE:512381
|
IN |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ECX's stock price target?
Not Available
ECX does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Epigenomics AG?
Projected CAGR
72%
Over the last 1 year, the compound annual growth rate for Revenue has been -92%. The projected CAGR for the next 4 years is 72%.